These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 35499120)
41. A qualitative exploration of the use of calendar landmarking instruments in cancer symptom research. Mills K; Emery J; Cheung C; Hall N; Birt L; Walter FM BMC Fam Pract; 2014 Oct; 15():167. PubMed ID: 25344200 [TBL] [Abstract][Full Text] [Related]
42. Biological gestational age and its calendar assessment with ultrasound. Part 2: Biological-calendar scales for prediction of birth-date. Klimek R; Klimek M Gynakol Geburtshilfliche Rundsch; 1992; 32(3):159-63. PubMed ID: 1467660 [TBL] [Abstract][Full Text] [Related]
43. Adaptation of the event history calendar for Ugandan adolescents. Saftner M; Thompson M; Ngabirano TD; McMorris BJ Glob Health Promot; 2020 Sep; 27(3):159-170. PubMed ID: 31749404 [TBL] [Abstract][Full Text] [Related]
44. Expression of Fas and anti-Fas-mediated apoptosis in human renal cell carcinoma. Inoue M; Yano H; Kojiro M Int J Oncol; 1996 Jul; 9(1):49-56. PubMed ID: 21541480 [TBL] [Abstract][Full Text] [Related]
45. Prospective study of fatty acid synthetase (FAS) expression in breast cancer and progression of disease. Hahnel R Int J Oncol; 1996 Aug; 9(2):253-5. PubMed ID: 21541508 [TBL] [Abstract][Full Text] [Related]
50. Prognostic value of the Fas/Fas ligand system in breast cancer. Bębenek M; Duś D; Koźlak J Contemp Oncol (Pozn); 2013; 17(2):120-2. PubMed ID: 23788976 [TBL] [Abstract][Full Text] [Related]
51. Soluble Fas/Apo-1 splicing variants and apoptosis. Cascino I; Papoff G; Eramo A; Ruberti G Front Biosci; 1996 Jan; 1():d12-8. PubMed ID: 9159204 [TBL] [Abstract][Full Text] [Related]
52. Fas and Fas ligand-mediated apoptosis and its role in autoimmune diabetes. Signore A; Annovazzi A; Gradini R; Liddi R; Ruberti G Diabetes Metab Rev; 1998 Sep; 14(3):197-206. PubMed ID: 9816469 [TBL] [Abstract][Full Text] [Related]
53. Fas and Fas ligand interactions in malignant disease. Owen-Schaub L; Chan H; Cusack JC; Roth J; Hill LL Int J Oncol; 2000 Jul; 17(1):5-12. PubMed ID: 10853011 [TBL] [Abstract][Full Text] [Related]
54. [Molecular biology of Fas antigen-Fas ligand system]. Mita E; Hayashi N Nihon Rinsho; 1996 Jul; 54(7):1736-40. PubMed ID: 8741659 [TBL] [Abstract][Full Text] [Related]
55. Epitope mapping of human Fas using peptide phage display. Abbasova SG; Shcheprova ZhM; Laman AG; Shepelyakovskaya AO; Baidakova LK; Rodionov IL; Kushlinskii NE Bull Exp Biol Med; 2007 Oct; 144(4):515-9. PubMed ID: 18642701 [TBL] [Abstract][Full Text] [Related]
56. Dual Role of Fas/FasL-Mediated Signal in Peripheral Immune Tolerance. Yamada A; Arakaki R; Saito M; Kudo Y; Ishimaru N Front Immunol; 2017; 8():403. PubMed ID: 28424702 [TBL] [Abstract][Full Text] [Related]
57. [The molecular structure and biological significance of soluble Fas]. Kobayashi S; Koike T Nihon Rinsho; 1996 Jul; 54(7):1741-6. PubMed ID: 8741660 [TBL] [Abstract][Full Text] [Related]
58. Expression profile of fas-fas ligand in spiral ganglion cells during apoptosis. Gu TW; Bae WY; Park HT; Lee JH; Kang MY; Jeong SW; Shin YK Clin Exp Otorhinolaryngol; 2014 Mar; 7(1):1-6. PubMed ID: 24587873 [TBL] [Abstract][Full Text] [Related]
59. [Involvement of Fas and Fas ligand in case of human fulminant hepatitis]. Ryo K; Kamogawa Y; Yamauchi K; Hayashi N Nihon Rinsho; 1996 Jul; 54(7):1965-9. PubMed ID: 8741696 [TBL] [Abstract][Full Text] [Related]